Nucleotech Medical Systems International Ltd, a active public limited company, was established on 13 April 2006 in Navi Mumbai, Maharashtra, India. Engaging in medical & laboratory equipment within the manufacturing sector, it holds CIN: U33100MH2006PLC161113. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹2.50 Cr and a paid-up capital of ₹2.50 Cr.
It upholds a compliant status. Its leadership includes Suman Arunkumar Saxena (Director), Arun Kumar Saxena (Director), Amaltash Arun Saxena (Director). Past directors included Gopal Das Saksena, Varsha Saxena, Monish Bhandari. It holds no open charges and ₹2.40 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No. 55, Ncz Midc, Taloja, Navi Mumbai, Maharashtra, 410208.
U33100MH2006PLC161113
161113
13 April 2006
₹2.50 Cr
₹2.50 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Nucleotech Medical Systems International Ltd — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suman Arunkumar Saxena | Director | 29 Aug 2014 | Current |
| Arun Kumar Saxena | Director | 05 Sep 2009 | Current |
| Amaltash Arun Saxena | Director | 30 Sep 2016 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 11 Apr 2014 | Past |
| Pramod Abcsdd | Director | 11 Sep 2015 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2016 | Past |
| Pramod Abcsdd | Managing Director | 29 Sep 2012 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2016 | Past |
| Pramod Abcsdd | Director | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nucleotech Medical Systems International Ltd, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.17% decrease. The company also saw a substantial fall in profitability, with a 2863.13% decrease in profit. The company's net worth dipped by a decrease of 4.74%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Nucleotech Medical Systems International had a promoter holding of 93.94% and a public holding of 6.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹24,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Nov 2007 | Bank Of Baroda | ₹1.20 Cr | Satisfied |
| 22 Nov 2007 | Bank Of Baroda | ₹1.20 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nucleotech Medical Systems International, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nucleotech Medical Systems International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleotech Medical Systems International's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Nucleotech Medical Systems International Ltd last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.
The activity Nucleotech Medical Systems International Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was completed.
Progress on A charge registered on 22 Nov 2007 via Charge ID 10080366 with Bank Of Baroda was fully satisfied on 19 Sep 2020. was documented.
The activity A charge registered on 22 Nov 2007 via Charge ID 10080384 with Bank Of Baroda was fully satisfied on 19 Sep 2020. was completed.
Progress on Amaltash Arun Saxena was appointed as a Director was appointed as a Director on 30 Sep 2016 & has been associated with this company since 9 years 1 month . was documented.
Progress on Suman Arunkumar Saxena was appointed as a Director was appointed as a Director on 29 Aug 2014 & has been associated with this company since 11 years 3 months . was documented.
The CIN of Nucleotech Medical Systems International Ltd is U33100MH2006PLC161113.
Nucleotech Medical Systems International Ltd is headquartered at Plot No. 55, Ncz Midc, Taloja, Navi Mumbai, Maharashtra, 410208.
Nucleotech Medical Systems International Ltd was incorporated on 13 April 2006.
The current directors of Nucleotech Medical Systems International Ltd are
The primary industry of Nucleotech Medical Systems International Ltd is Manufacturing.
Nucleotech Medical Systems International Ltd is unlisted.
The authorized capital of Nucleotech Medical Systems International Ltd is ₹2.50 Cr, and the paid-up capital is ₹2.50 Cr.
The compliance status of Nucleotech Medical Systems International Ltd is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX